Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement

Klimek, L; Jutel, M; Akdis, C; Bousquet, J; Akdis, M; Bachert, C; Agache, I; Ansotegui, I; Bedbrook, A; Bosnic-Anticevich, S; Canonica, GW; Chivato, T; Cruz, AA; Czarlewski, W; Del Giacco, S; Du, H; Fonseca, JA; Gao, YD; Haahtela, T; Hoffmann-Sommergruber, K; Ivancevich, JC; Khaltaev, N; Knol, EF; Kuna, P; Larenas-Linnemann, D; Melén, E; Mullol, J; Naclerio, R; Ohta, K; Okamoto, Y; O'Mahony, L; Onorato, GL; Papadopoulos, NG; Pawankar, R; Pfaar, O; Samolinski, B; Schwarze, J; Toppila-Salmi, S; Shamji, MH; Ventura, MT; Valiulis, A; Yorgancioglu, A; Matricardi, P; Zuberbier, T

Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement

Authors

Publisher

WILEY

Abstract

The current COVID-19 pandemic influences many aspects of personal and social interaction, including patient contacts with health care providers and the manner in which allergy care is provided and maintained. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on inducing an appropriate immune response in the allergic patient. This manuscript outlines the EAACI recommendations regarding AIT during the COVID-19 pandemic and aims at supporting allergists and all physicians performing AIT in their current daily practice with clear recommendations on how to perform treatment during the pandemic and in SARS-CoV-2 infected patients.